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Background: Current guidelines suggest to consider dual antiplatelet therapy (DAPT)
continuation for longer than 12 months in selected patients with myocardial infarc-
tion (MI).
Hypothesis: We sought to assess the criteria used by cardiologists in daily practice to
select patients with a history of MI eligible for DAPT continuation beyond 1 year.
Methods: We analyzed data from the EYESHOT Post-MI, a prospective, observa-
tional, nationwide study aimed to evaluate the management of patients presenting to
cardiologists 1 to 3 years from the last MI event.
Results: Out of the 1633 post-MI patients enrolled in the study between March and
December 2017, 557 (34.1%) were on DAPT at the time of enrolment, and
450 (27.6%) were prescribed DAPT after cardiologist assessment. At multivariate
analyses, a percutaneous coronary intervention (PCI) with multiple stents and the
presence of peripheral artery disease (PAD) resulted as independent predictors of
DAPT continuation, while atrial fibrillation was the only independent predictor of
DAPT interruption for patients both at the second and the third year from MI at
enrolment and the time of discharge/end of the visit.
Conclusions: Risk scores recommended by current guidelines for guiding decisions
on DAPT duration are underused and misused in clinical practice. A PCI with multiple
stents and a history of PAD resulted as the clinical variables more frequently associ-
ated with DAPT continuation beyond 1 year from the index MI.
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1 | INTRODUCTION
Current guidelines suggest that continuation of dual antiplatelet ther-
apy (DAPT) for longer than 12 months should be considered in
patients with myocardial infarction (MI) who have tolerated DAPT
without bleeding complications.1,2 This recommendation is based on
recent randomized clinical trials suggesting that DAPT prolongation
reduces the rate of recurrent ischemic events in post-MI patients,
compared with aspirin alone.3,4 However, these benefits come at the
cost of increased risk of bleeding, raising the question about how
to identify the ideal patient profile who could safely prolong
DAPT.1,2,5,6 Although predictors of DAPT interruption have been
already identified in large international registries,7-9 specific appraisals
underlying the decision on the extension of DAPT have been poorly
investigated.10,11
Using data from the EYESHOT (EmploYEd antithrombotic thera-
pies in patients with acute coronary Syndromes HOspitalized in iTaly)
Post-MI study12 we sought to evaluate the criteria used by cardiolo-
gists in daily clinical practice for selecting post-MI patients eligible for
DAPT continuation beyond 1 year.
2 | METHODS
The methods used for the EYESHOT Post-MI study have been
described previously.12 Briefly, it was a prospective, observational,
nationwide registry of consecutive patients with a prior MI managed
by cardiologists. All patients admitted in cardiology units and/or
ambulatory clinics during a period of 3 months with a documented
history of presumed spontaneous MI event (non-ST-elevation,
NSTEMI or ST-elevation-MI, STEMI) occurred between 1 and 3 years
before enrolment have been included.12 Patients were enrolled at the
beginning of outpatient or day-hospital visit or at hospital admission.
Physicians were asked to report medications at enrolment and at the
end of the visit or hospital discharge.
The Italian Association of Hospital Cardiologists (ANMCO)
designed, endorsed, and conducted the study. All patients were
informed of the nature and aims of the study and asked to sign an
informed consent for the anonymous management of their individual
data. Local Institutional Review Boards (IRB) approved the study pro-
tocol according to the current Italian rules. Data were collected in dif-
ferent periods of consecutive 3 months in each site between 1 March
2017 and 16 December 2017. Over these periods, 1633 consecutive
patients [median 22 (IQR 15-28) months from MI] were enrolled:
1028 (63.0%) presenting to a cardiologist during the second [median
17 (IQR 14-21) months] and 605 (37.0%) during the third year from
MI [median 30 (IQR 27-33) months].12 The study has been carried out
in 165 cardiology centers. Most of the patients were enrolled during
outpatient or day-hospital visits (84%) and the remaining during hospi-
tal admissions (16%).12
Data were collected using a web-based, electronic case report
form with the central database located at the ANMCO Research Cen-
ter. By using a validation plan, integrated in the data entry software,
data were checked for missing or contradictory entries and values out
of the normal range.
2.1 | Statistical analysis
Categorical variables are presented as number and percentages and
compared by the χ2 test. Normally distributed, continuous variables
are presented as mean and SD (SD) and compared by means of t test,
while not normally distributed variables are reported as median and
interquartile range (IQR)and assessed by the Mann-Whitney U test.
The study cohort was stratified according to the treatment with
DAPT at the time of enrolment.
Clinically relevant variables were included in a multivariable model
(logistic regression), to identify the independent predictors of DAPT
assumption at the time of enrolment and after hospital discharge from
a cardiology ward or at the end of the visit by cardiologist among
patients in the second and the third year from the index MI. The vari-
ables included in the logistic model were: age, gender, diabetes
mellitus, renal insufficiency, peripheral artery disease (PAD), history of
major bleeding events or surgery, heart failure, atrial fibrillation, pres-
ence of symptoms, prior revascularization, number of stent implanted
(≤2 vs >2), type of last myocardial infarction (STEMI vs NSTEMI), type
of enrolment (hospital admission vs outpatient visit). A P value < .05
was considered statistically significant. All tests were two-sided. Ana-
lyses were performed with SPSS system software, version 24.
3 | RESULTS
Out of the 1633 post-MI patients enrolled, 557 (34.1%) were on
DAPT at the time of enrolment (413 in the second and 144 in the
third year from the index MI). At the time of discharge/end of the
visit, 450 (27.6%) were prescribed DAPT (317 in the second and
133 in the third year from the index MI) (Figure 1). At the end of the
visit/hospital discharge a DAPT was initiated by cardiologists in 4%
(44/1076) of patients, while in 27% of cases (151/557) DAPT was
withdrawn (Figure 1). Out of the 151 patients who interrupted DAPT
after the visit by a cardiologist, only five (3.3%) withdrew at least one
antiplatelet agent for a planned major surgery; in the remaining
146 patients DAPT was interrupted for clinical reasons.
F IGURE 1 Patients flow-chart
1114 DE LUCA ET AL.
Baseline characteristics of patients on DAPT vs those not receiv-
ing DAPT at enrolment are shown in Table 1. Patients on DAPT were
on average younger (64 vs 66 years, P = .002) and had a shorter time
since index MI (20 vs 23 months, P < .001). In addition, patients on
DAPT had less frequently atrial fibrillation (6.8% vs 15.9%, P < .0001)
but did have a higher incidence of PAD compared to patients without
DAPT at enrolment (9.3% vs 5.6%, P = .005).
PCI with multiple stents implantation was more frequent in
patients on DAPT (30.7% vs 17.1%, P < .0001). Systolic blood pres-
sure (129 vs 131 mmHg, P = .015) was lower in patients on DAPT
whereas levels of triglycerides were higher (110 vs 103 mg/dL,
P = .049) as compared to patients without DAPT (Table 1).
Among patients receiving DAPT, the most frequently used combi-
nation was aspirin and clopidogrel for both patients in the second and
third year from MI (Table 2).
Scores for the assessment of ischemic or bleeding risk were used
in 8.1% and 6.9% of patients, respectively (Figure 2). The GRACE and
the HAS-BLEED resulted as the risk scores mostly used for the evalu-
ation of ischemic or bleeding risk, respectively (Figure 2). Ischemic risk
scores were used in 9.5% of the patients on DAPT and in 7.4% of
TABLE 1 Clinical characteristics and laboratory variables of patients on DAPT and those not receiving DAPT at the time of enrolment
no DAPT N = 1076 DAPT N = 557 P value
Age, mean ± SD 66 ± 11 64 ± 12 .002
Age ≥ 75 years, n (%) 258 (24.0) 100 (18.0) .005
Males, n (%) 857 (79.6) 457 (82.0) .263
Type MI, n (%) .076
STEMI 561 (52.1) 264 (47.4)
NSTEMI 515 (47.9) 293 (52.6)
Months since MI, mean ± SD 23 ± 7 20 ± 7 <.0001
BMI, mean ± SD 27.2 ± 4 27.2 ± 4 .969
Active smokers, n (%) 199 (18.5) 109 (19.6) .829
Diabetes mellitus, n (%) 293 (27.2) 168 (30.2) .223
Hypertension,a n (%) 832 (77.3) 451 (81.0) .098
Hypercholesterolemia, n (%) 790 (73.4) 422 (75.8) .311
Atrial fibrillation, n (%) 171 (15.9) 38 (6.8) <.0001
Renal dysfunction,b n (%) 124 (11.5) 79 (14.2) .133
Peripheral artery disease,c n (%) 60 (5.6) 52 (9.3) .005
COPD, n (%) 120 (11.2) 67 (12.0) .623
Stroke/TIA, n (%) 48 (4.5) 20 (3.6) .436
Major bleeding,d n (%) 39 (3.6) 11 (2.0) .070
Heart failure, n (%) 159 (14.8) 94 (16.9) .279
PCI with >2 stent, n (%) 184 (17.1) 171 (30.7) <.0001
Prior CABG, n (%) 111 (10.3) 60 (10.8) .798
Ejection fraction, %, mean ± SD 48 ± 18 47 ± 18 .066
Systolic blood pressure, mmHg, mean ± SD 131 ± 18 129 ± 17 .015
Heart rate, bpm, mean ± SD 67 ± 12 67 ± 11 .114
Hemoglobin, g/dL, median [IQR] 14.0 [12.6-15.0] 13,8 [12.3-14.9] .303
Creatinine, mg/dL, median [IQR] 1.0 [0.8-1.2] 1,0 [0.8-1.2] .503
Total cholesterol, mg/dL, median [IQR] 140 [122-162] 139 [122-165] .876
LDL cholesterol, mg/dL, median [IQR] 72 [56-91] 70 [58-90] .963
Triglycerides, mg/dL, median [IQR] 103 [79-141] 110 [83-155] .0049
Glycemia, mg/dL, median [IQR] 103 [92-119] 103 [93-122] .573
aSBP≥140 mmHg or diastolic blood pressure ≥ 90 mmHg or use of blood pressure lowering drugs.
bDialysis, history of renal transplant or creatinine levels >1.5 mg/dL.
cHistory of claudication; amputation for arterial insufficiency; aorta-iliac occlusive disease reconstruction surgery; peripheral vascular bypass surgery,
angioplasty, or stent; documented abdominal aortic aneurysm, aneurysm repair or stent; and documented positive non-invasive testing such as abnormal
ankle-brachial index or pulse volume recording.
dFatal bleeding, or clinically evident bleeding with hemoglobin reduction ≥2 g/dL or requiring transfusion or hospitalization.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; HR, heart rate; LDL, low density lipoprotein; SBP, systolic blood
pressure; STEMI, ST-elevation myocardial infarction; TIA, transient ischemic attack.
DE LUCA ET AL. 1115
patients without DAPT (P = .153); whereas bleeding risk scores were
used in 8.1% and 6.2% of patients on DAPT and without DAPT,
respectively (P = .179).
At multivariate analyses, PCI with multiple stents and PAD
resulted as independent predictors of DAPT continuation, while atrial
fibrillation was the sole independent predictor of DAPT interruption
for both patients at the second and the third year from MI at enrol-
ment and the time of discharge/end of the visit (Figure 3).
4 | DISCUSSION
The present analysis of a nationwide study on consecutive patients
managed by cardiologists 1-3 years after a MI demonstrates that:
(a) DAPT was withdrawn in approximately one of three patients
enrolled and in less than 5% of cases DAPT was initiated after cardiol-
ogist' assessment; (b) Risk scores for the identification of patients who
can benefit from DAPT prolongation are mis- and underused in clinical
practice; (c) Patients with a complex PCI and a history of PAD are
those who more frequently continue DAPT beyond 1 year from the
index MI.
In post-MI patients, the cardiovascular risk remains substantially
elevated beyond the first year.13-15 The REACH (REduction of
Atherothrombosis for Continued Health) registry showed an incidence
of recurrent cardiovascular events of 18% at 4 years in patients with
history of MI or stroke.13 Accordingly, the APOLLO dataset, which
links registries and administrative data, demonstrated that the risk of
cardiovascular events in MI survivors is approximately 20% across the
first 3 years from MI.14,15 In this setting, prolonged DAPT has been
shown to be an effective therapeutic strategy to prevent recurrent
ischemic events.1-4 Nonetheless, because continued antiplatelet ther-
apy is also associated with increased risk of bleeding, it is necessary to
weigh this risk against the potential benefit.1-4 Decisions about dura-
tion of DAPT are best made on an individual basis and should inte-
grate several clinical variables. In this regard, novel risk scores have
been specifically designed to guide and inform decision making for
optimal DAPT duration.16 However, most of the frequently used risk
scores for assessing ischemic events or major bleedings in our cohort
were originally developed and validated for the prediction of events
occurring mainly during hospital stay or at short term follow-up after
a MI or in the setting of atrial fibrillation.17,18 As a result, the applica-
tion of these risk scores to decide upon DAPT prolongation seems
inappropriate, as only limited data exist exploring their value to guide
DAPT duration. On the other hand, risk scores specifically validated
for assessing DAPT duration, such as the DAPT or the PRECISE-DAPT
(PREdicting bleeding Complications In patients undergoing Stent
TABLE 2 Type of P2Y12 inhibitor associated with aspirin at enrolment and after cardiologist' assessment according to the time from last MI
(12-24 months vs 24-36 months)
Time from MI
12-24 months 25-36 months
DAPT at enrolment Clopidogrel 188 (45.5%) 114 (79.2%)
N = 557
Prasugrel 60 (14.5%) 5 (3.5%)
Ticagrelor 90 mg bid 143 (34.6%) 21 (14.6%)
Ticagrelor 60 mg bid 20 (4.8%) 3 (0.2%)
Ticlopidine 2 (0.5%) 1 (0.1%)
Total 413 144
DAPT after cardiologist assessment Clopidogrel 177 (55.8%) 112 (84.2%)
N = 450
Prasugrel 27 (8.5%) 2 (1.5%)
Ticagrelor 90 mg bid 64 (20.2%) 15 (11.3%)
Ticagrelor 60 mg bid 47 (14.8%) 3 (2.3%)
Ticlopidine 2 (0.6%) 1 (0.8%)
Total 317 133
F IGURE 2 Use of scores for the assessment of ischemic or
bleeding risk
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implantation and subsEquent Dual Anti Platelet Therapy) scores,19,20
have been extremely underused in our registry.
Several studies demonstrated major bleeding events and urgent
surgery are the most common reasons for early DAPT interruption.7-9
However, few have investigated the reasons why cardiologists pro-
long or interrupt DAPT beyond the first year after a MI.10,11 The EPI-
COR study (long-term follow-up of antithrombotic management
patterns in acute coronary syndrome patients), conducted in
2010-2011 in 20 countries, showed that more than half of patients
with MI remained on DAPT beyond 12 months in Europe and Latin
America.10 Subsequently, the TIGRIS registry, conducted in
2013-2014 in 25 countries, documented DAPT continuation beyond
1 year in 12% of post-MI patients with high-risk features enrolled in
Europe, 25% in North America and 40% in Asia-Pacific countries.11 In
both international registries,10,11 the presence of frequent PCI with
multiple stenting represented the most important determinants of
DAPT continuation 1 year after the index MI. The EYESHOT Post-MI
study differs from the above mentioned registries since we enrolled
patients exclusively managed by specialists in a nationwide setting
and within the first 3 years from the last MI event, allowing assess-
ment of the different selection criteria for DAPT continuation
according to the timing from the first recommended year of DAPT
and excluding patients who already interrupted DAPT for major
bleeding events, need for major surgery, cultural and/or economic
reasons. Nevertheless, even in our analysis, a complex PCI with multi-
ple stents implantation, together with the presence of PAD, resulted
as independent predictor of DAPT continuation for both patients in
the second and in the third year from MI. In this regard, emerging evi-
dences suggest that the magnitude of the benefit with long-term
DAPT is progressively greater per increase in PCI procedural complex-
ity.21,22 Similarly, several international registries and analyses from
clinical trial databases have demonstrated an increased risk of recur-
rent ischemic events among patients with MI and PAD, including
those receiving an early and effective coronary revascularization, and
recent studies also suggested a survival benefit of DAPT continuation
in these patients.23
On the other hand, the presence of atrial fibrillation needing oral
anticoagulation therapy was an independent predictor of DAPT inter-
ruption in our analysis. This finding is in accordance with recent guide-
lines and consensus documents recommending a shorter duration of
DAPT in order to reduce the risk of major bleeding events.1,2,24
4.1 | Study limitations
Our study must be evaluated in the light of the known limitations of
observational, cross-sectional studies. In addition, even if the partici-
pating centers were asked to include in the registry all consecutive
post-MI patients, we were not able to verify the enrolment process,
due to the absence of administrative auditing. We believe that it is
unlikely however that selective enrolment in few sites may have sub-
stantially changed the study results. Finally, even if we tried to collect
in the CRF all the possible variables responsible for DAPT interruption
or continuation, we cannot exclude some reasons have not been
gathered.
F IGURE 3 Multivariable analysis on DAPT assumption at the time of enrolment for patients in the second (Panel A) and third (Panel B) year
from the last MI and after cardiologist assessment for patients in the second (Panel C) and third (Panel D) year from the last MI
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5 | CONCLUSIONS
In this contemporary, nationwide, real-world study on consecutive
patients managed by cardiologists 1 to 3 years after a MI, risk scores
recommended by current guidelines for guiding decisions on DAPT
duration have been used in a small number of cases. A PCI with multi-
ple stents and a history of PAD resulted as the clinical variables more
frequently associated with DAPT continuation beyond 1 year from
the index MI. These findings may have important implications for edu-
cational programs to improve adherence to current guidelines.
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Saronno (D. Nassiacos, S. Meloni, B. Barco); Trento (R. Bonmassari,
A. Bertoldi, F. Tedoldi); Andria (M. Cannone, G. Valenti, R.L. Musci);
Bari, San Paolo (P. Caldarola, N. Locuratolo, L. Sublimi Saponetti); Bre-
scia (L. Gentili, C. Maiandi); Chieti (M. Caputo, C.A. Capparuccia);
Milano, Maggiore Policlinico (T. Tonella, F.M. Massari); Verbania
(A. Lupi, M. Tessitori, M. Montano); Milano, S.M. Nascente
(A. Scaglione, A. Torri); Reggio Emilia (G. Tortorella, A. Navazio); Bol-
zano (R. Cemin, L. Latina); Castellanza (D. Briguglia, R. Marino);
Lumezzane (S. Scalvini, E. Zanelli); Montescano (V. Paganini,
G. Riboni); Pordenone (E. Leiballi, A. Della Mattia); Rovereto
(F. Imperadore); Seriate (M. Tespili, G. Santangelo); Borgomanero
(U. Parravicini, P. Dellavesa); Cecina (R. Testa, E. Venturini); Fossano
(M. Feola, M. Testa); Lentini (V. Crisci, M. Tramontana); Lido di Cama-
iore (L. Robiglio); Rivoli (F. Varbella, I. Meynet); Roma, Villa Betania
(A. Galati, A. Maddaluna); Arzignano (C. Bilato, I. Loddo); Augusta
(G. Licciardello, L. Cassaniti); Benevento, G. Rummo (M. Scherillo,
D. Formigli); Castel Volturno (L. Marullo, L. Chianese); Corato
(C. Paolillo, A.P.A. De Santis); Foggia (N.D. Brunetti, D. Bottigliero);
Roma, Casilino (R. Della Bona, M.B. Giannico); San Donato Milanese,
IRCCS, Cardiologia Riabilitativa (R. Tramarin, S. Lucibello); Ancona,
Riuniti (G.P. Perna, M. Marini); Campobasso (A.R. Colavita); Catania,
Garibaldi-Nesima (M.M. Gulizia, G.M. Francese); Cuggiono
(M. Mariani, F. Collauto); Magenta (M. D'Urbano, R. Naio); Messina
(G. Andò, F. Saporito); Milano, Monzino (E.M. Assanelli, A. Cabiati);
Paola (A. Crivaro, S. Alberti); Rieti (I. Marchese); Roma, Clinica Città di
Roma (T. Nejat, S. Refice); Roma, P.O.S. Filippo Neri, Cardiologia e
UTIC (F. Colivicchi, A. Aiello); Roma, P.O.S. Filippo Neri, Card. Riab.-P.
O. Salus (A. Galati, G.R. Cristinziani); Roma, Umberto Primo (F. Barillà,
R Iorio); Sanremo (G. Mascelli, S.N. Tartaglione); Santa Maria Capua
Vetere (G. Di Chiara, D. D'Andrea); Ancona, INRCA (R. Antonicelli,
G. Malatesta); Firenze (C. Di Mario, A. Mattesini); Spoleto
(L. Tramontana, S. Conti); Viterbo (L. Sommariva, A. Celestini); Catania,
Cannizzaro (F. Amico, S. Giubilato); Galatina (A.F. Amico, M. De Fil-
ippis); Gavardo (G.F. Pasini, M Triggiani); Manfredonia (V. Ferrara,
S. Cappetti); Milano, San Paolo (S. Carugo, S. Lucreziotti); San
Benedetto Del Tronto (M. Persico, G. Gizzi); Cefalù (T. Cipolla,
A. Caronia); Fidenza (E. Buia, P. Pastori); Foligno (M. Scarpignato,
E. Biscottini); Legnano (F. Poletti, C. Vimercati); Milano, Niguarda, Car-
diologia (R. Pirola); Negrar (E. Barbieri, C Dugo); Osio Sotto (N. De
Cesare, M.L. De Benedictis); Reggio Calabria, Madonna della Con-
solazione (A. Ruggeri); San Fermo della Battaglia (C. Campana,
S. Bonura); San Giovanni Rotondo (C. Vigna, N. Marchese); Sondalo
(N.G. Partesana, P. Bandini); Cassano delle Murge (G. Farinola,
D. Santoro); Catanzaro, Pugliese (F. Cassadonte); Empoli (F. Calabrò,
M. Sansoni); Erice (M.G. Abrignani, F. Bonura); Fermo (D. Gabrielli,
M. Benvenuto); Lecce (A. Liso, T. Passero); Milano, CTO (I. Mori,
B. Pozzoni); Roma, S.G. Addolorata (F. Prati, M.L. Finocchiaro); Sor-
rento (N. Tufano); Melito di Porto Salvo (B. Miserrafiti, V. Lacquaniti);
Mestre, San Marco (F. Del Piccolo, B. Mohamad); Moncalieri (M.T.
Spinnler, V. Bovolo); Palermo, Casa di Cura Candela (E. Rebulla,
M. Pieri); Pescara (L. Paloscia, D. Di Clemente); Piossasco
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(G. Mazzucco, A. Micanti); Ponte San Pietro (P. Peci, O. Ornago);
Roma, Aurelia Hospital (F. Proietti, M. Michisanti); Scandiano
(A. Reverzani, A. Donatini); Avola (P. Costa, S. Russo); Belluno
(E. Franceschini Grisolia, L. Mario); Boscotrecase (F. Di Palma,
F. Dell'Aquila); Busto Arsizio (A. Maestroni, SI Caico); Castellammare
di Stabia (G. De Caro, L. Attianese); Esine (S. Perotti, V. Cotti Cometti);
Genova, Padre Antero Micone (D. Astengo); Guastalla (A. Navazio,
E. Guerri); Milano, S. Raffaele (D. Cianflone, F. Maranta); Napoli, Fond.
Evangelica Betania (N. Esposito, M. Malvezzi Caracciolo D'Aquino);
Nola (L. Caliendo, C. Ricci); Reggio Calabria, Bianchi Melacrino Morelli
(C.P. Ceruso, S. Lanteri); Roma, S. Pietro FBF (R. Serdoz, E. Bruno);
San Felice a Cancello (C. De Matteis, C. Campagnuolo); San Giuseppe
Vesuviano (M.A. Ammirati, V.M. Corrado); Arco (M.A. Amado Eleas);
Aversa (L. Fattore); Avezzano (C. Ippoliti); Conegliano (G. Turiano);
Feltre (C. Piergentili); Gallarate (S.I. Caico); Genova, S. Martino
(F. Chiarella); Napoli, S.G. Bosco (P. Capogrosso); Pavia, ICS Maugeri
SPA Società Benefit (M. Perotti); Pescia (S. Di Marco); Pozzuoli
(G. Sibilio); Sessa Aurunca (L. Di Lorenzo); Taranto (A. Aurelio); Vicenza
(A.B. Ramondo); Bari, Policlinico (D. Zanna); Castelfranco Veneto
(C. Cernetti); Giugliano in Campania (G. Napolitano); Imola (S. Negroni);
Latina (N. Alessandri); Mestre, Dell'Angelo (F. Rigo); Molfetta (F. Giusti);
Nuoro (G. Casu); Peschiera Del Garda (A. Vicentini); Policoro (G. Calculli);
Pomezia (M.S. Fera); Vittoria (G.V. Lettica); Volterra (G. Vagheggini);
Bergamo (A. Pitì); Caserta, Villa del Sole (A. Porfidia); Ciriè (A. Di Leo);
Ivrea (A. Ravera); Licata (E. Ciotta); Mirano (S. Saccà); Napoli, AORN
Cardarelli, Cardiologia Generale c/Riabilitazione (O. Silvestri); Piombino
(S. Isidori); S. Omero (P. Natali); San Bonifacio (M. Anselmi); San Donato
Milanese, IRCCS, Cardiologia c/UTIC (L. Testa); Sesto San Giovanni
(A. Antonelli); Sondrio (E. Tavasci); Telese (G. Furgi); Teramo
(A. Lavorgna); Treviso (N. Gasparetto); Udine (T. Bisceglia).
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